A clinical utility study claimed use of the Afirma Gene Expression Classifier, developed by Veracyte Inc., can significantly reduce unnecessary surgeries in thyroid cancer diagnoses. The study was published in Cancer Cytopathology.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
